Humana shares surged about 14.5% in premarket trading on Friday after federal regulators released 2027 Medicare Advantage Star Ratings that made the insurer the primary beneficiary of the update. The Centers for Medicare & Medicaid Services restored a 4-star rating to Humana's flagship Medicare Advantage contract, known as H5216, which covers more than 2 million members, up from 3.5 stars.
Star ratings matter because they influence the bonus payments that Medicare pays to higher-rated plans, and because they affect marketing flexibility and enrollment. A move to 4 stars on a contract of this size is therefore financially meaningful, and the market reaction reflects how heavily the insurer's profit outlook depends on Medicare Advantage performance and on the quality scores that regulators assign each year.
CVS Health moved the other way, falling about 3.2% premarket after a setback in its Medicare Advantage Star Ratings that threatens future bonus payments and profit margins. The reaction shows how relative the annual ratings can feel to investors, who tend to rotate toward insurers with improving scores and away from those facing downgrades.
For Humana, the upgrade removes a significant overhang. Ratings below the 4-star threshold can limit an insurer's access to quality bonus payments, so restoring that level on a contract covering more than 2 million members improves the earnings outlook tied to the plan. The scale of the premarket gap also shows how much risk investors had assigned to a less favorable outcome.
CVS investors face the opposite calculation. The reported setback threatens future bonus payments and profit margins, and Medicare Advantage is a core earnings engine for large managed-care companies. Whether the damage proves temporary depends on how quickly the company can improve quality measures, appeal scoring decisions where possible, and adjust benefit design for coming plan years.
Friday's backdrop adds volatility. Futures were rising as oil prices eased and technology stocks attempted to recover from a selloff tied to AI valuation concerns, but inflation expectations and bond yields remain elevated. Defensive healthcare names can attract flows in such environments, though a double-digit premarket move invites profit-taking once regular trading begins and liquidity deepens.
Traders should consider how much of the news is already reflected in prices. After a gap of this size, the risk-reward for chasing Humana at the open is less attractive than it was for investors who held through the announcement, while CVS may find buyers if the decline is judged an overreaction. Analyst revisions to 2027 estimates over the coming days will provide a clearer read on the earnings impact.
Longer term, the ratings underscore how sensitive Medicare Advantage economics are to quality scores and regulatory decisions. Investors should watch for company statements on the details of the ratings, any plans to contest results, and commentary on how the changes affect membership growth and margins heading into the next enrollment season.